Xuanzhu Biopharmaceutical | ApexOnco - Clinical Trials news and analysis

“The insights provided by the analysts are great”

Director New Product Planning

Morphosys

Click here for more information

Data insights

8 July 2025

The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.

Regulatory

7 March 2024

Recent Quick take